Pharmacists in Demopolis, AL Accepting Medicare
7 Pharmacists found. Showing 1 - 7
 Mr. John Ashton Beaudry, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 312 Us Highway 80 E, Demopolis, AL 36732 Phone: 334-289-3657 |
 Teresa Boone Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 951 Us Highway 80 W # B, Demopolis, AL 36732 Phone: 334-289-8989 |
Raymond Leon Boone, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 951 Us Highway 80 W # B, Demopolis, AL 36732 Phone: 334-289-9982 Fax: 334-289-3276 |
Sharon Edmondson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 969 Us Highway 80 W, Demopolis, AL 36732 Phone: 334-289-9897 |
Caitlin Moore, PHARMD., RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 969 Us Highway 80 W, Demopolis, AL 36732 Phone: 334-289-9897 |
Trameika M. Hawkins, PHARM D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 505 Us Highway 80 W Ste A, Demopolis, AL 36732 Phone: 334-287-1200 Fax: 334-287-0509 |
Dr. Jamie Lynn Tucker, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1107 Lillian Lane, Demopolis, AL 36732 Phone: 334-507-8266 |
News Archive
New study enrolls young adults to evaluate SARS-CoV-2 infection
The Prevent COVID U study, which launched in late March 2021 to evaluate SARS-CoV-2 infection and transmission among university students vaccinated with the Moderna COVID-19 Vaccine, has expanded beyond the university setting to enroll young adults ages 18 through 29 years and will now also include people in this age group who choose not to receive a vaccine.
New research shows that ketogenic diets may increase risk of Type 2 diabetes
New research published in The Journal of Physiology indicates that ketogenic diets, which are low carbohydrate high fat eating plans that are known to lead to weight loss, may cause an increased risk of Type 2 diabetes in the early stage of the diet.
Losartan improves effectiveness of nanotherapeutics against cancer
Low doses of an inexpensive, FDA-approved hypertension medication may improve the results of nanotherapeutic approaches to cancer treatment. In a report in the early edition of Proceedings of the National Academy of Sciences, Massachusetts General Hospital (MGH) investigators describe experiments showing that the generic drug losartan, by modifying the network of collagen fibers that characterizes most solid tumors, improved the effectiveness of two nanotherapeutics against several types of cancer.
BigThink.com launches breakthroughs: Discussion highlighting cutting-edge cancer research
Everyone knows someone that has been touched by cancer. Over one and a half million Americans will be diagnosed with some form of cancer in 2011, and more than 560,000 will die from the disease, accounting for 1 out of every 5 deaths.
› Verified 5 days ago
Pharmacists
Dentists
Counselors
Clinical Social Workers
Occupational Therapists
Marriage Counselors